New drug candidates

A board to discuss future MS therapies in early stage (Phase I or II) trials.

New drug candidates

Postby scoobyjude » Tue Nov 07, 2006 6:24 pm

Critical Outcome Technologies Inc. Announces the Final Selection of its Library of Orally Available Lead Compounds for the Treatment of Acute Multiple Sclerosis 07 November 2006

Critical Outcome Technologies Inc. a computational drug discovery and pre-clinical drug development company, has completed the discovery, optimisation and final selection of its library of lead compounds for the oral treatment of acute Multiple Sclerosis. The compounds have been engineered to be orally available, have low toxicity, cross the blood brain barrier and selectively inhibit Vascular Endothelial Growth Factor (VEGF-R) and Platelet Derived Growth Factor (PDGF-R) receptor kinases.
The first four lead candidates are now being synthesised at Dalton Pharma Services, Toronto, Canada, prior to undergoing efficacy and toxicity testing in a validated animal model of acute allergic encephalitis.

Critical Outcome Technologies Inc. expects the synthesis to be completed by the end of January 2007 and will advise the market accordingly.

SOURCE: Critical Outcome Technologies Inc.


Cannasat Therapeutics Inc. announces NRC-IRAP funding for CAT 210 07 November 2006

Cannasat Therapeutics Inc. is pleased to announce a contribution agreement with the National Research Council Canada Industrial Research Assistance Program ("NRC-IRAP") for pre-clinical research and development of CAT 210. CAT 210 is Cannasat's second product in development that targets the treatment of neuropathic pain with cannabinoids.
Pre-clinical studies for CAT 210 will be conducted at the Pain Centre at the McGill University Health Centre (MUHC). Early stage formulation work for CAT 210 will take place at the Cannasat's R&D facilities in Edmonton, Canada.

"We are very pleased to be sharing the costs of this project with NRC-IRAP for development of CAT 210 as part of our R&D efforts in developing novel cannabinoid drug products. Development of CAT 210 expands our pipeline of cannabinoid-based pharmaceuticals for neuropathic pain, a condition for which there is a large underserved market. We are also very excited to be working with the Pain Centre at McGill, one of the world's leading institutions in pain research," states David Hill, Chief Executive Officer of Cannasat Therapeutics.

Neuropathic pain arises from injury to the peripheral or central nervous system and is associated with trauma or diseases such as diabetes, herpes zoster, HIV/AIDS, and multiple sclerosis. Affecting approximately 26 million people worldwide, neuropathic pain is one of the most difficult forms of pain to treat - only 50 per cent of patients respond to current treatment options. As such, there is a large unmet need for new therapies.

ABOUT CANNASAT THERAPEUTICS INC.

Cannasat Therapeutics is researching the therapeutic benefits of cannabis and developing new cannabinoid pharmaceutical products. Cannasat is pursuing two complementary business strategies. The first consists of development of novel cannabinoid-based pharmaceutical products through application of drug delivery technologies to be introduced to the market through the traditional regulatory drug approval process. The second is to promote medicinal cannabis research and education with Cannasat's business partner, Prairie Plant Systems Inc., the only government licensed grower and distributor of medicinal cannabis in Canada.

Source: Cannasat Therapeutics Inc.
User avatar
scoobyjude
Family Elder
 
Posts: 516
Joined: Sat Feb 18, 2006 3:00 pm
Location: suburb of Chicago, IL USA

Advertisement

Return to Drug Pipeline

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service

cron